1-10 of 10
Diana Abbott, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-136120
Published: 2020
Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Shanshan Pei, PhD, Daniel A Pollyea, MD, Annika Gustafson, Mohammad Minhajuddin, PhD, Brett M. Stevens, PhD, Haobin Ye, PhD, Anagha Inguva, BSc, Maria L Amaya, MD PhD, Anna Krug, BS, Courtney L Jones, PhD, Biniam Adane, PhD, Amanda Winters, MD PhD, Nabilah Khan, Jessica Ponder, PhD, Jeffrey Schowinsky, Andrew Hammes, MS, Diana Abbott, PhD, Jason R Myers, MS, John M Ashton, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Haley E. Ramsey, PhDMSc, Michael R. Savona, MD, Stephen W. Fesik, PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 185.
https://doi.org/10.1182/blood-2019-131390
Published: 2019
Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5897.
https://doi.org/10.1182/blood-2019-126344
Published: 2019
Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4126.
https://doi.org/10.1182/blood-2019-129208
Published: 2019
Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Amanda Winters, MD PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Brett M. Stevens, PhD, Shanshan Pei, PhD, Jeffrey Schowinsky, Diana Abbott, PhD, Andrew Hammes, MS, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, PA-C, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, MD, Craig T Jordan, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2638.
https://doi.org/10.1182/blood-2019-122120
Published: 2019
Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 432.
https://doi.org/10.1182/blood-2018-99-111507
Published: 2018
Journal Articles

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, PhDBS, Courtney L Jones, PhD, Amanda Winters, MDPhD, James Dugan, MD, Diana Abbott, PhD, Michael R. Savona, MD, Stephen W. Fesik, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 909.
https://doi.org/10.1182/blood-2018-99-119806
Published: 2018
Journal Articles

Bone Marrow Cellularity and Recovery of Blood Counts after Venetoclax and Azacitidine in Elderly Acute Myeloid Leukemia Patients Unfit for Induction Chemotherapy

James Dugan, MD, Daniel A. Pollyea, MD, Diana Abbott, PhD, Theodore Schultheiss, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5086.
https://doi.org/10.1182/blood.V130.Suppl_1.5086.5086
Published: 2017
Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 181.
https://doi.org/10.1182/blood.V130.Suppl_1.181.181
Published: 2017
Journal Articles

Genome Wide Scan of Complete Blood Count (CBC) Measures Suggests Strong Linkage of Red Blood Cell (RBC) Count to Chromosome 4q25.

Diana Abbott, PhD, Kai Wang, PhD, Amy Shapiro, MD, Trudy Burns, PhD, Jorge Di Paola, MD
Journal: Blood
Blood (2007) 110 (11): 1729.
https://doi.org/10.1182/blood.V110.11.1729.1729
Published: 2007